Celgene Corporation (NASDAQ: CELG) made yet another major acquisition last week, picking up Receptos, Inc. (NASDAQ: RCPT) for $7.2 billion. The acquisition significantly boosts Celgene’s Inflammation and Immunology portfolio with the addition of Receptos’ lead product candidate, Ozanimod, which is in Phase 3 tests to treat immune-inflammatory indications in irritable bowel syndrome and relapsing multiple sclerosis. This is Celgene’s biggest deal in 2015, out of the six it has announced. So far, the drug maker has splurged nearly $8.8 billion on acquisitions, collaborations with other drug makers and licensing deals.
Celgene Continues Its Buying Spree
by Lisa Phillips | Jul 20, 2015 3:37 pm | Biotechnology
Categories
- Ambulatory Surgery Centers
- Behavioral Health Care
- Biotechnology
- CDMO
- CRO
- eHealth
- Healthcare M&A News Leads
- Healthcare Market Updates
- Healthcare Staffing
- Home Health & Hospice
- Hospitals
- Laboratories, MRI & Dialysis
- Long-Term Care
- Managed Care
- Medical Devices
- Medical Office Buildings
- Occupational Health
- Other Services
- Pharmaceuticals
- Physician Medical Groups
- Private Equity
- Rehabilitation
- SPAC
- Specialty Pharmacies
- Uncategorized
- Urgent Care Centers